Entwicklung von neuen topischen Substanzen zur Therapie der atopischen Dermatitis

Online survey to identify current challenges in atopic dermatitis management and guideline implementation in German-speaking countries

(2022) Stephan Traidl et al.   EUROPEAN JOURNAL OF DERMATOLOGY

Aryl Hydrocarbon Receptor/nuclear factor E2‐related factor 2 (AHR/NRF2) Signaling: A Novel Therapeutic Target for Atopic Dermatitis

(2022) Jonwei Hwang et al.   EXPERIMENTAL DERMATOLOGY

Einschätzungen zur Therapie der moderaten bis schweren atopischen Dermatitis mit Januskinaseinhibitoren

(2022) Felix Lauffer et al.   HAUTARZT

A Phase 1b, Randomized, Single-Center Trial of Topical Cerdulatinib (DMVT-502) in Patients with Mild-to-Moderate Atopic Dermatitis

(2021) Stephen C. Piscitelli et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies

(2021) Xiaohua Gong et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Efficacy and Safety of Ruxolitinib Cream for the Treatment of Atopic Dermatitis: Results From Two Phase 3, Randomized, Double-Blind Studies

(2021) Kim Papp et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Topical therapy of atopic dermatitis with a focus on pimecrolimus

(2021) T. Luger et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Difamilast ointment, a selective phosphodiesterase 4 inhibitor, in paediatric patients with atopic dermatitis: A phase 3 randomised double‐blind, vehicle‐controlled trial

(2021) H. Saeki et al.   BRITISH JOURNAL OF DERMATOLOGY

Epidemiologie und Therapie von erwachsenen Patienten mit atopischer Dermatitis

(2021) Henny Anna Zietze et al.   HAUTARZT

Safety of topical corticosteroids in atopic eczema: an umbrella review

(2021) Emma Axon et al.   BMJ Open

Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study

(2020) Hidemi Nakagawa et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Topical antibiotics in the dermatological clinical practice: Indications, efficacy, and adverse effects

(2020) Domenico Bonamonte et al.   Dermatologic Therapy

Efficacy and Patient-Reported Outcomes from a Phase IIb, Randomized Clinical Trial of Tapinarof Cream for the Treatment of Adolescents and Adults with Atopic Dermatitis

(2020) Amy S. Paller et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Association Between Topical Calcineurin Inhibitor Use and Keratinocyte Carcinoma Risk Among Adults With Atopic Dermatitis

(2020) Maryam M. Asgari et al.   JAMA Dermatology

Unmet medical needs in the treatment of atopic dermatitis in infants: An Expert consensus on safety and efficacy of pimecrolimus

(2020) Thomas Luger et al.   PEDIATRIC ALLERGY AND IMMUNOLOGY

Efficacy and safety of topical OPA-15406, a new phosphodiesterase 4 inhibitor, in Japanese patients with atopic dermatitis for 8 weeks: A phase 2, randomized, double-blind, placebo-controlled study

(2019) Hidehisa Saeki et al.   JOURNAL OF DERMATOLOGY

Aryl-Hydrocarbon-Rezeptor als Zielstruktur für neue Medikamente bei Psoriasis und atopischer Dermatitis

(2019) Hans F. Merk   HAUTARZT

Long‐term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis

(2019) Hidemi Nakagawa et al.   JOURNAL OF DERMATOLOGY

Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis

(2016) Elaine C. Siegfried et al.   BMC Pediatrics

Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial

(2016) R. Bissonnette et al.   BRITISH JOURNAL OF DERMATOLOGY

Cellular and molecular immunologic mechanisms in patients with atopic dermatitis

(2016) Thomas Werfel et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled study

(2016) Jon M. Hanifin et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults

(2016) Amy S. Paller et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis

(2013) Mayte Suárez-Fariñas et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY